Glendale Biomed Profile
Key Indicators
- Authorised Capital ₹ 2.20 Cr
as on 15-12-2024
- Paid Up Capital ₹ 2.20 Cr
as on 15-12-2024
- Company Age 8 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.47 Cr
as on 15-12-2024
- Satisfied Charges ₹ 5.10 Cr
as on 15-12-2024
- Revenue 45.77%
(FY 2021)
- Profit 884.89%
(FY 2021)
- Ebitda 2061.09%
(FY 2021)
- Net Worth 54.54%
(FY 2021)
- Total Assets -41.84%
(FY 2021)
About Glendale Biomed
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.20 Cr and a paid-up capital of Rs 2.20 Cr.
The company currently has active open charges totaling ₹3.47 Cr. The company has closed loans amounting to ₹5.10 Cr, as per Ministry of Corporate Affairs (MCA) records.
Pramod Yadav and Suraj Singh serve as directors at the Company.
- CIN/LLPIN
U74120MH2016PTC273873
- Company No.
273873
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Mar 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- LocationMumbai, Maharashtra
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Glendale Biomed?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pramod Yadav  | Director | 15-Dec-2017 | Current |
| Suraj Singh | Additional Director | 20-Apr-2020 | Current |
Financial Performance of Glendale Biomed.
Glendale Biomed Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 45.77% increase. The company also saw a substantial improvement in profitability, with a 884.89% increase in profit. The company's net worth Soared by an impressive increase of 54.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Glendale Biomed?
Unlock access to Glendale Biomed's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Glendale Organics Private LimitedActive 3 years 2 monthsPramod Yadav and Suraj Singh are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 02 Nov 2022 | ₹9.20 M | Open |
Others Creation Date: 20 Jun 2022 | ₹6.50 M | Open |
Canara Bank Creation Date: 28 Jul 2021 | ₹1.90 Cr | Open |
How Many Employees Work at Glendale Biomed?
Unlock and access historical data on people associated with Glendale Biomed, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Glendale Biomed, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Glendale Biomed's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
